U.S. Markets closed

EMA adopts positive opinion on Teva's Lonquex

The Committee for Medicinal Products for Human Use, CHMP, announced it adopted a positive opinion, recommending the granting of a marketing authorization for Lonquex, 6 mg, solution for injection intended for prophylaxis against chemotherapy-induced neutropenia. The applicant for this medicinal product is Teva Pharma B.V., the EMA said.